BioSpace News Archive

Altoida, Inc. today announced key appointments across clinical affairs, marketing, and operations to support the continued advancement of its digital phenotypes and programs.

KSQ Therapeutics today announced the initiation of dosing in the combination therapy portion of Study KSQ-4279-1101, a Phase 1 clinical study of KSQ-4279 in patients with advanced solid tumors.

Abata Therapeutics today announced that it has appointed Ellen Cahir-McFarland, Ph.D., as its Chief Scientific Officer.

Generate Biomedicines today announced that Jane Mendillo has been appointed to its board of directors.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,517,545 under the title “Treatment of Moderate and Severe Gastroparesis.”

Amarin Corporation plc (NASDAQ:AMRN) today announced that Switzerland’s Swissmedic has granted approval to VAZKEPA (icosapent ethyl). Swissmedic approved VAZKEPA to reduce risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥ 150 mg/dL [≥ 1.7 mmol/L]) and established cardiovascular disease, or diabetes and at least one other cardiovascular risk factor.

Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Bendamustine Lyo. Injection to its line of chemotherapy drugs.

Sarcopenia is a degenerative condition that tends to affect older people, and low muscle mass and strength are the main indicators.

HeartBeam, Inc. (NASDAQ: BEAT)today announced it has signed an agreement (the “Agreement”) with Evolve Manufacturing Technologies (“Evolve”), a contract medical device manufacturing company, to build the credit card-sized AIMIGo 3D vector electrocardiogram (VECG) recording device that provides a 12 lead ECG readout for remote heart attack detection.

Essential Pharma announces that it has completed the acquisition of HALDOL® and HALDOL® Decanoate from Janssen Pharmaceutica NV.